Bio-Rad director gains shares via RSU vesting

Hinckley Greg K reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Hinckley Greg K reported acquisition or exercise transactions in this Form 4 filing.

Bio-Rad Laboratories director Greg K. Hinckley increased his direct equity stake through routine equity compensation. On April 21, 2026, 407 restricted stock units vested and were settled into 407 shares of Bio-Rad Class A common stock. Following this settlement, Hinckley directly held 1,215 shares of Class A common stock.

On the same date, he received a new grant of 369 restricted stock units, each representing a contingent right to one share of Bio-Rad Class A common stock. These units will vest 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.

Insider Trade Summary

407 shares exercised/converted

Exercise 3 txns

Insider Hinckley Greg K

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	369	$0.00	$0.00
Exercise	Restricted Stock Units	407	$0.00	$0.00
Exercise	Bio-Rad A Common Stock	407	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 369 contracts (Direct); Bio-Rad A Common Stock — 1,215 shares (Direct)

Footnotes (3)

1. F1. Shares of Class A common stock acquired on the vesting of restricted stock units.
2. F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
3. F3. The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders.

Key Figures

RSUs vested: 407 units New RSU grant: 369 units Shares after transaction: 1,215 shares +2 more

5 metrics

RSUs vested 407 units Converted into 407 Bio-Rad Class A common shares on April 21, 2026

New RSU grant 369 units Restricted stock units granted with contingent right to one Class A share each

Shares after transaction 1,215 shares Total Bio-Rad Class A common stock directly held after Form 4 transactions

Exercise/grant price $0.00 per share/unit Reported transaction and conversion price for the RSU vesting and grant

RSU vesting schedule 100% cliff vesting Vests on earlier of first grant anniversary or next annual stockholders’ meeting

Key Terms

Restricted Stock Units, contingent right, Class A common stock

3 terms

Restricted Stock Units financial

"The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock."

Class A common stock financial

"Shares of Class A common stock acquired on the vesting of restricted stock units."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Greg K. Hinckley report for BIO on April 21, 2026?

Greg K. Hinckley reported routine equity compensation activity. 407 restricted stock units vested into 407 shares of Bio-Rad Class A common stock, and he received a new grant of 369 restricted stock units, all at a stated price of $0.00 per unit or share.

How many Bio-Rad A common shares does Greg K. Hinckley hold after this Form 4?

After these transactions, Hinckley directly holds 1,215 Class A shares. This reflects the addition of 407 shares received upon the vesting of restricted stock units. The filing shows this total as his direct Class A common stock holdings following the reported transactions.

What restricted stock unit grant did BIO director Greg K. Hinckley receive?

Hinckley received a grant of 369 restricted stock units. Each unit represents a contingent right to receive one share of Bio-Rad Class A common stock, with all units scheduled to vest 100% on the earlier of the first grant anniversary or the next annual stockholders’ meeting.

How were the 407 restricted stock units in BIO’s Form 4 settled?

The 407 restricted stock units were settled in Class A common shares. Upon vesting, they converted into 407 shares of Bio-Rad Class A common stock, increasing Greg K. Hinckley’s direct share ownership as reported in the Form 4 filing.

What are the vesting terms for Greg K. Hinckley’s new BIO restricted stock units?

The 369 new restricted stock units vest in a single 100% tranche. Vesting occurs on the earlier of the first anniversary of the grant date or the date of Bio-Rad Laboratories’ next annual meeting of stockholders, according to the footnotes in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 03:26 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hinckley Greg K

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CALIFORNIA 94547

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	04/21/2026		M		407(1)	A	$0	1,215	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	04/21/2026		A		369		(3)	(3)	Bio-Rad A Common Stock	369	$0	369	D
Restricted Stock Units	$0(2)	04/21/2026		M			407	(3)	(3)	Bio-Rad A Common Stock	407	$0	0	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

3. The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders.

Remarks:

	/s/ Gregory K. Hinckley	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)